The latest news about tungsten and tungsten stocks like Kennametal Inc. (KMT), Colt Resources Inc (GTP.V), Woulfe Mining Corp. (WOF.V) and Tungsten Corp. (TUNG).
Despite being the subject of a movie (“A Civil Action”) about pollution and going bankrupt to avoid asbestos claims, chemical stock W.R. Grace & Co. (GRA) has been solid performer for investors during its decade long bankruptcy proceedings.
The Tractor Supply Company (TSCO) is in much better shape and in a better position than Orchard Supply Hardware Stores Corp (OSH) – which just filed for bankrupcty and looks set to be acquired by Lowe's Companies, Inc. (LOW).
QCOR stock has generally recovered from last year’s smackdown, which is why we’ve become less enthusiastic about the upside and more concerned about the potential for the company to disappoint. Third party prescription data shows that Acthar has been doing very well this month (especially last week) – likely as a result of Acthar’s introduction to a number of new indications in recent months, although it’s worth noting that the “weak hand” shorts are likely to have covered at this point.
The Supreme Court's ruling on gene patents opens the way for Cancer Genetics (OTCQB: CGIX) to enter new markets for genetic testing.
Illumina Inc. (NASDAQ:ILMN), Complete Genomics, Inc. (NASDAQ:GNOM), and Sequenom, Inc. (NASDAQ:SQNM) may all be in the same business, but one of them is a superior opportunity right now.
Clovis has presented some truly amazing data for the prospective NSCLC drug CO-1686 at ASCO 2013, which explains the magnitude of the recent CLVS rally. Despite the notion that the company is still an early-stage developer, the ASCO data and the hope that the company will see an accelerated approval process is likely to support the stock for quite some time.
Like Herbalife Ltd. (HLF), small cap Blyth, Inc. (BTH) is in the direct selling business and it has the dubious distinction of being the most shorted NYSE stock.
Edward Snowden is not the first Booz Allen Hamilton Holding Corporation (BAH) source for leaks and might impact the firm’s ability to win new contracts.
Many claim that OPKO is overvalued based on the market prospects of its pipeline compounds, although the company is generating substantial value with business partnerships and equity investments in companies like RXi and Tesaro. RXi in particular has become a favorite of OPKO with the accumulation of 67.2 M shares (19.9% of shares outstanding) up to this point, making a full acquisition of RXi by OPKO very possible.
